Pricing Log in Create free account

Artelo Biosciences, Inc. (ARTL) vs Carisma Therapeutics Inc. (CARM)

Artelo Biosciences, Inc. and Carisma Therapeutics Inc. are both Biotechnology companies. Artelo Biosciences, Inc. and Carisma Therapeutics Inc. are of similar size ($1.5M and $1.5M). Carisma Therapeutics Inc. has the higher net margin (14.4% vs 0.00%) and the higher return on invested capital (0.00% vs −865.9%). Across the 12 metrics below, Carisma Therapeutics Inc. leads on 9 and Artelo Biosciences, Inc. on 3.

Valuation

Metric ARTL CARM Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.16 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.31 n/m 0.64
EV/Sales n/m (0.05) 9.21
Earnings yield (4,348.52%) 0.00% (33.15%)
Free cash flow yield (1,553.13%) 0.00% (25.50%)

Profitability

Metric ARTL CARM Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 19.36% 0.00%
Net margin 0.00% 14.36% 0.00%
Free cash flow margin 0.00% (38.79%) 0.00%
Return on equity (705.71%) (134.11%) (56.36%)
Return on assets (234.30%) 33.09% (48.04%)
Return on invested capital (865.85%) 0.00% 0.00%

Growth

Metric ARTL CARM Biotechnology median
Revenue growth (TTM) — 170.48% 6.02%
EPS growth (last fiscal year) 31.57% 43.68% 30.26%
Revenue growth, 5-year CAGR — 115.24% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARTL CARM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.00 0.86 4.72
Net debt to EBITDA 0.05 0.30 0.96

Dividend

Metric ARTL CARM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ARTL CARM Biotechnology median
Market cap 1.50m 1.52m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack